CN1903187B - Compound propofol injection containing local anesthetic and preparation process - Google Patents
Compound propofol injection containing local anesthetic and preparation process Download PDFInfo
- Publication number
- CN1903187B CN1903187B CN2006100712321A CN200610071232A CN1903187B CN 1903187 B CN1903187 B CN 1903187B CN 2006100712321 A CN2006100712321 A CN 2006100712321A CN 200610071232 A CN200610071232 A CN 200610071232A CN 1903187 B CN1903187 B CN 1903187B
- Authority
- CN
- China
- Prior art keywords
- propofol
- injection
- compound
- stir
- take
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 41
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229960004134 propofol Drugs 0.000 title claims abstract description 37
- 238000002347 injection Methods 0.000 title claims abstract description 21
- 239000007924 injection Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000003589 local anesthetic agent Substances 0.000 title abstract 4
- 239000000839 emulsion Substances 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000008215 water for injection Substances 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 19
- 235000011187 glycerol Nutrition 0.000 claims description 12
- 239000004530 micro-emulsion Substances 0.000 claims description 11
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims description 8
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 7
- 229960000502 poloxamer Drugs 0.000 claims description 7
- 229920001983 poloxamer Polymers 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000002960 lipid emulsion Substances 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 2
- 235000013772 propylene glycol Nutrition 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 11
- 239000003995 emulsifying agent Substances 0.000 abstract description 9
- 230000036407 pain Effects 0.000 abstract description 8
- 239000003963 antioxidant agent Substances 0.000 abstract description 7
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract description 5
- 229960004194 lidocaine Drugs 0.000 abstract description 5
- 229960001807 prilocaine Drugs 0.000 abstract description 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 abstract description 4
- 229960004919 procaine Drugs 0.000 abstract description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 abstract description 4
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 abstract description 3
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 abstract description 3
- 230000003444 anaesthetic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 229960003150 bupivacaine Drugs 0.000 abstract description 3
- 229960002409 mepivacaine Drugs 0.000 abstract description 3
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 abstract description 3
- 229960001549 ropivacaine Drugs 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 238000010253 intravenous injection Methods 0.000 abstract description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract description 2
- 239000008158 vegetable oil Substances 0.000 abstract description 2
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 229960005015 local anesthetics Drugs 0.000 description 12
- 238000002156 mixing Methods 0.000 description 10
- CRBJBYGJVIBWIY-UHFFFAOYSA-N 2-isopropylphenol Chemical compound CC(C)C1=CC=CC=C1O CRBJBYGJVIBWIY-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 238000005360 mashing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 239000007957 coemulsifier Substances 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 239000010773 plant oil Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- -1 Palmic acid diol ester Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940072271 diprivan Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- XSEOYPMPHHCUBN-FGYWBSQSSA-N hydroxylated lecithin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCC[C@@H](O)[C@H](O)CCCCCCCC XSEOYPMPHHCUBN-FGYWBSQSSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound propofol injection containing local anesthetic and a preparation process thereof. Contains propofol and local anesthetic as effective medicinal components, and each 1000ml of injection contains: 1000-20000mg of propofol, 50-50000mg of procaine, or 50-50000mg of lidocaine, or 50-50000mg of prilocaine, or 50-50000mg of bupivacaine, or 50-50000mg of mepivacaine or 50-50000mg of ropivacaine, and each 1000ml contains 0-200000mg of refined vegetable oil for injection; emulsifier 50-600000 mg; 200-5000mg of isoosmotic adjusting agent; 50-10000 mg of antioxidant; adjusting the pH value to 6.0-9.0 by using a pH regulator; proper amount of water for injection. The formulation has many of the outstanding advantages of propofol as a novel intravenous whole anesthetic. On the other hand, the addition of the local anesthetic remarkably reduces the incidence rate and the degree of pain of the common propofol emulsion injection. Improves the compliance of patients, widens the clinical application prospect, and is a safe and effective intravenous injection anesthetic.
Description
Technical field
The present invention relates to medical technical field, definite saying so contains the compound isopropyl phenol injection and the preparation technology of local anaesthetics.
Background technology
Propofol, promptly 2, the 6-diisopropyl phenol is a kind of novel systemic vein injecting anesthetic medicine.It has that onset is rapid, action time is short, revive rapidly fully, untoward reaction is few, do not stay sequela, (can be used for induction of anesthesia, keep and epidural anesthesia assisted etc.) applied widely, dosage are easy to good characteristics such as grasp.
Since 1977 find its narcotic activity, aspect preparation, carried out a lot of researchs, and obtained clinical practice more and more widely.The pharmacodynamic study of propofol shows, maybe be because due to gastrointestinal tract destroy, and propofol oral administration non-activity.At present, mostly the dosage form of clinical practice both at home and abroad is injectable emulsion, like the lipomul (Diprivan) of Britain prompt sharp Kanggong department production etc.But propofol Emulsion has an outstanding shortcoming, and the pain incidence rate is higher when injecting exactly, and patient's compliance is relatively poor.Recently the relevant propofol injection pain degree that alleviates, the research that reduces the pain incidence rate is also more.The corresponding strategy of taking clinically is more, mainly comprises two aspects: the one, and to the influence factors' such as material of the temperature of injection site, injection, injection speed, syringe research, the effect that is obtained is not ideal enough; On the other hand, adopt drug combination exactly, before medication, propofol Emulsion and some drugs mixed use, Combined application has benefit caine, procaine, prilocaine, fentanyl, an atropine etc. usually.According to the clinical application screening, local anaesthetics such as lignocaine are the ideal medicament that a type and propofol mix use, but operations such as preclinical mixing have increased the contaminated probability of medicine again, and drug level is difficult to grasp.
Summary of the invention
The object of the invention is to provide compound isopropyl phenol injection and the preparation technology who contains local anaesthetics.
The invention provides the method for preparing of compound fat Emulsion, and emulsion particle diameter is controlled at the 0.1-0.8 micron; The method for preparing of compound recipe submicron emulsion, microemulsion is provided, and particle diameter has been controlled in the ideal scope; The method for preparing of Injectable compound preparation is provided.Above-mentioned compound preparation comprises propofol, local anaesthetics (procaine or lignocaine or prilocaine or bupivacaine or mepivacaine or ropivacaine), refined plant oil, emulsifying agent (comprising coemulsifier), isoosmotic adjusting agent, antioxidant, pH regulator agent etc.It is characterized in that: above pharmacology component can be prepared into compound fat Emulsion, compound recipe submicronized emulsion, compound recipe microemulsion and Injectable compound preparation.The every 1000mL of compound fat Emulsion contains: propofol 1000-20000mg, local anaesthetics 50-50000mg, refined plant oil 10-200000mg; Emulsifying agent 50-50000mg, glycerol 200-50000mg, antioxidant 50-10000mg; PH to 6.0～9.0 are transferred in the pH regulator agent; Surplus is water for injection, and the emulsion particle diameter scope should be at the 0.1-0.8 micron, preferably less than 0.5 micron.On the basis of above-mentioned emulsion; Remove refined plant oil; Change the consumption of corresponding emulsifying agent, can prepare the compound recipe submicronized emulsion, it is characterized in that: pH to 6.0～9.0 are transferred in every 1000mL propofol-containing 1000-10000mg, local anaesthetics 50-50000mg, emulsifying agent 50-10000mg, coemulsifier 10000-600000mg, glycerol 200-50000mg, antioxidant 50-10000mg, pH regulator agent; Surplus is water for injection, and the emulsion particle diameter scope should be at the 0.1-0.5 micron.The increase and decrease respective components; Change the ratio of profit phase; Can prepare the compound recipe microemulsion; It is characterized in that: pH to 6.0～9.0 are transferred in every 1000mL propofol-containing 1000-10000mg, local anaesthetics 50-50000mg, emulsifying agent 50-10000mg, coemulsifier 10000-600000mg, glycerol 200-50000mg, pH regulator agent, and surplus is water for injection, and the emulsion particle diameter scope should be about 0.2 micron.On the basis of above-mentioned emulsion, adding mannitol, lactose can prepare Injectable compound preparation, it is characterized in that: every 1000mL propofol-containing 1000-20000mg, local anaesthetics 50-50000mg, mannitol 5000-300000mg, lactose 10000-300000mg.The preparation technology of compound isopropyl phenol Emulsion (comprising: compound fat Emulsion, compound recipe Emulsion, compound recipe submicronized emulsion, compound recipe microemulsion) is characterized in that: emulsifying agent, propofol and an amount of solvent of recipe quantity got in (1), is heated to 45-80 ℃, makes its dissolving mixing; Lignocaine, isoosmotic adjusting agent, antioxidant and an amount of solvent of getting recipe quantity are miscible, also are heated to 45-80 ℃.(2) with the liquid of gained in (1), mixing disperses through tissue mashing machine, and per minute 20000 changes, and three minutes, triplicate.(3) add other component and be preheated to 45-80 ℃ of water for injection in right amount, cross the high pressure dispersing emulsification machine, three times repeatedly, sampling, microscopically is observed particle diameter, when emulsion particle diameter meets the requirements, stops.(4) filter, N2 is filled in fill, seal, and sterilization, numbering gets product.The preparation of Injectable compound preparation may further comprise the steps: on the basis of compound recipe Emulsion, add the mannitol and the lactose of recipe quantity, lyophilization is collected content and is got final product.
The preferential component of compound preparation of the present invention is: in every 1000ml injection, contain
Propofol 10000mg
Procaine 2000mg
Or lignocaine 2000mg
Or prilocaine 2000mg
Or bupivacaine 2000mg
Or mepivacaine 2000mg
Or ropivacaine 2000mg
Its characteristic also is: every 1000mL contains injection refined plant oil 100000mg; Emulsifying agent (comprising coemulsifier) 50-600000mg; Isoosmotic adjusting agent 200-5000mg; Antioxidant 50-10000mg; PH. regulator is transferred pH to 6.0～9.0; (Injectable compound preparation contains mannitol 5000-300000mg, lactose 10000-300000), water for injection was an amount of.
Solvent is selected from following: the mixture of one or more in ethanol, dichloromethane, chloroform, the methanol.
The injection vegetable oil be selected from following: the mixture of one or more in soybean oil, Oleum sesami, safranine caul-fat, Oleum Arachidis hypogaeae semen, the Semen Maydis oil.
Soybean oil is selected from following: the mixture of one or more in LCT, medium chain triglyceride, glycerin mono-fatty acid ester, the glycerol list linoleate.
Emulsifying agent is selected from following: lecithin, hydroxylated lecithin, soybean phospholipid, soybean lecithin, hydrogenated soya phosphatide, Ovum Gallus domesticus Flavus lecithin, poloxamer, cholesterol, (deoxidation) sodium cholate, polyglycereol Palmic acid diol ester, acetic acid esters of mono, polyoxyethylene anhydrate the sorbic acid cetylate, gather hexanediol, 1, the mixture of one or more among 2-propylene glycol, the Drewmulse.
Isoosmotic adjusting agent is selected from following: the mixture of one or more in glucose, sodium chloride, glycerol, sorbitol, xylitol, the mannitol.
The pH regulator agent is selected from following: the mixture of one or more in hydrochloric acid, phosphoric acid, citric acid (sodium), sodium hydroxide (potassium), glacial acetic acid, buffer agent such as sodium dihydrogen phosphate and the sodium hydrogen phosphate.
Antioxidant is selected from following: a kind of or inflated with nitrogen in vitamin E, vitamin C, cysteine, the methionine.
The invention has the advantages that:
Propofol is as a kind of novel intravenous injection GENERAL ANESTHETICS, its determined curative effect, drug safety.The propofol lipomul is used early, technology maturation.On the basis of lipomul, add the compound preparation that local anaesthetics makes, patient's pain reduces the pain incidence rate when the pharmacodynamic experiment proof can significantly alleviate injection.
Compound isopropyl phenol microemulsion and submicronized emulsion not only have the effect that eases the pain, and (microemulsion is transparent, and particle diameter is about 0.2 micron owing to particle in the emulsion is less; Submicron emulsion is translucent, and size ratio microemulsion particle diameter is big slightly), the Emulsion physical stability is good, has solved the bad difficult problem of emulsion stability.
The preparation of Injectable compound preparation has further solved the stability of formulation problem, makes things convenient for the storage and the circulation of product simultaneously.
The effect that alleviates injection pain is played in the adding of local anaesthetics.Simultaneously, the equal curative effect of used local anaesthetics is accurate, and relevant administration is experienced clinically, and its price is lower, so after propofol made compound recipe with it, the cost of preparation did not obviously rise.Above effect truly has actual effect all through evidence.
The specific embodiment:
Following instance will be done further elaboration to the present invention, but not limit content of the present invention.
Embodiment 1 (compound isopropyl phenol lipomul): Ovum Gallus domesticus Flavus lecithin 20g is got in (1), refined soybean oil 150g, and propofol 10g is preheated to 80 ℃ of stirrings, mixing.(2) taking polyethylene glycol 50g, glycerol 20g, lidocaine hydrochloride 2g and an amount of water for injection are preheated to 80 ℃ of stirrings, mixing.(3) (2) are added in (1), the limit edged stirs, and disperses through tissue mashing machine, and per minute 20000 changes, and three minutes, triplicate.(4) add and be preheated to 80 ℃ of waters for injection in right amount, cross the high pressure dispersing emulsification machine to full dose 1000ml, three times repeatedly, sampling, microscopically is observed particle diameter, when emulsion particle diameter meets the requirements, stops.(5) filter, N is filled in fill
2, seal, sterilization, numbering gets product.
Embodiment 2 (compound isopropyl phenol submicronized emulsion): Ovum Gallus domesticus Flavus lecithin 15g is got in (1), and propofol 10g is preheated to 80 ℃ of stirrings, mixing.(2) get 1,2-propylene glycol 100g, poloxamer 20g, glycerol 25g, lidocaine hydrochloride 1g and an amount of water for injection are preheated to 80 ℃ of stirrings, mixing.(3) (2) are added in (1), the limit edged stirs, and disperses through tissue mashing machine, and per minute 20000 changes, and three minutes, triplicate.(4) add and be preheated to 80 ℃ of waters for injection in right amount, cross the high pressure dispersing emulsification machine to full dose 1000ml, three times repeatedly, sampling, microscopically is observed particle diameter, when emulsion particle diameter meets the requirements, stops.(5) filter, N is filled in fill
2, seal, sterilization, numbering gets product.
Embodiment 3 (compound isopropyl phenol microemulsion): propofol 10g, V are got in (1)
E2g is preheated to 80 ℃ of stirrings, mixing.(2) get 1,2-propylene glycol 500g, poloxamer 30g, glycerol 15g, lidocaine hydrochloride 5g and an amount of water for injection are preheated to 80 ℃ of stirrings, mixing.(3) (2) are added in (1), the limit edged stirs, and disperses through tissue mashing machine, and per minute 20000 changes, and three minutes, triplicate.(4) add and be preheated to 80 ℃ of waters for injection in right amount, cross the high pressure dispersing emulsification machine to full dose 1000ml, three times repeatedly, sampling, microscopically is observed particle diameter, when emulsion particle diameter meets the requirements, stops.(5) filter, N is filled in fill
2, seal, sterilization, numbering gets product.
Embodiment 4 (Injectable compound preparation): propofol 20g is got in (1), Ovum Gallus domesticus Flavus lecithin 12g, poloxamer 40g; Lidocaine hydrochloride 30g and an amount of water for injection are preheated to 80 ℃ of stirrings, and mixing disperses through tissue mashing machine; Per minute 20000 changes, and three minutes, triplicate.Add mannitol 30g, lactose 20g is stirred to mix homogeneously.Cross the high pressure dispersing emulsification machine, three times repeatedly, 0.22 μ m membrane filtration pours into cillin bottle, lyophilization.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100712321A CN1903187B (en) | 2006-03-21 | 2006-03-21 | Compound propofol injection containing local anesthetic and preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100712321A CN1903187B (en) | 2006-03-21 | 2006-03-21 | Compound propofol injection containing local anesthetic and preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1903187A CN1903187A (en) | 2007-01-31 |
| CN1903187B true CN1903187B (en) | 2012-05-30 |
Family
ID=37672647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100712321A Expired - Fee Related CN1903187B (en) | 2006-03-21 | 2006-03-21 | Compound propofol injection containing local anesthetic and preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1903187B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370619A (en) * | 2010-08-18 | 2012-03-14 | 罗和国 | Fat-emulsion-emulsified local anesthetic |
| CN106902362B (en) * | 2017-02-13 | 2018-04-13 | 牡丹江医学院 | A kind of anaesthetic preparation for ultrasonic guidance and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714520A (en) * | 1994-03-22 | 1998-02-03 | Zeneca Limited | Propofol compostion containing edetate |
-
2006
- 2006-03-21 CN CN2006100712321A patent/CN1903187B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714520A (en) * | 1994-03-22 | 1998-02-03 | Zeneca Limited | Propofol compostion containing edetate |
Non-Patent Citations (1)
| Title |
|---|
| JP特开2002-179562A 2002.06.26 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1903187A (en) | 2007-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11304913B2 (en) | Analgesic compositions | |
| CN103565743B (en) | Tranexamic acid external preparation for skin nanometer formulation and its production and use | |
| CN103381142B (en) | A kind of ginsenoside Rh1 self-microemulsion composition and its preparation method and application | |
| AU2016258642A1 (en) | Cabazitaxel fat emulsion injection, and preparation method and use thereof | |
| WO2006039231A2 (en) | Topical formulations for the treatment of depression with s adenosyl methionine | |
| WO2011113301A1 (en) | Self-emulsifying formulation of taxanes and preparation method thereof | |
| CN1903187B (en) | Compound propofol injection containing local anesthetic and preparation process | |
| CN101288682B (en) | Microemulsion containing brucea javanica oil and preparation method thereof | |
| CN101416942A (en) | Nimodipine sub micro-emulsion injection and preparation method thereof | |
| CN107661294A (en) | Drug for hypertension Fat Emulsion Injection and preparation method thereof | |
| CN101332176A (en) | Medicine composition for injecting cinnarizine lipid microsphere and preparation method thereof | |
| CN105311622B (en) | A kind of combination medicine that treating pain and its preparation, preparation method | |
| CN103054799B (en) | Amiodarone hydrochloride injection emulsion and preparation method thereof | |
| CN102258467B (en) | Formula and preparation of intravenous injection sustained-release fat emulsion of arteannuin and derivative thereof | |
| CN102824307A (en) | Propofol medicinal composition for injection | |
| CN1698588A (en) | Propofol oral anesthetic and preparation method thereof | |
| CN103432074B (en) | Praziquantel emulsion injection and preparation technology thereof | |
| CN1331462C (en) | Self microemulsion of total dragon's blood flavone | |
| CN113559060B (en) | Submicron emulsion of propolis phospholipid complex and preparation method thereof | |
| CN103705439B (en) | Lipid gel pharmaceutical preparation and its production and use | |
| CN102038636A (en) | Taxane medicine solution containing chelating agent and preparation method thereof | |
| CN1989972A (en) | Finasteroid oral preparation and method for preparing same | |
| CN104473869A (en) | Esmolol fat emulsion and preparation method thereof | |
| WO2023278665A1 (en) | Methods for treatment of opioid use disorder with cannabinoids | |
| CN1857255A (en) | Bilobalide B emulsion for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20170321 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |